Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Gimsilumab
KIN-1901 · 2 trials · 3 indications
"Incidence" is defined as the percent of subjects that died by Day 43
| Arm | Type | Description |
|---|---|---|
| Gimsilumab | EXPERIMENTAL | Gimsilumab 400 mg on Day 1 Gimsilumab 200 mg on Day 8 |
| Placebo | PLACEBO_COMPARATOR | Normal saline on Day 1 Normal saline on Day 8 |
| KIN-1901 | EXPERIMENTAL | Single or repeat (once weekly for 4 weeks) KIN-1901 subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| Gimsilumab | DRUG | Gimsilumab is a fully human monoclonal antibody (mAb). |
| Placebo | DRUG | Normal saline |
| KIN-1901 | DRUG | KIN-1901 is a fully human monoclonal antibody (mAb). |
Inclusion Criteria: 1. Male or non-pregnant female age ≥18 years, inclusive 2. Subject (or legally authorized representative) is able and willing to provide written informed consent, which includes compliance with study requirements and restrictions listed in the consent form 3. Has laboratory-conf...
KIN-1901 is an investigational small molecule developed by Roivant Sciences Ltd. for inflammation. It has been studied in a Phase 1 clinical trial that enrolled healthy subjects and subjects with ankylosing spondylitis. KIN-1901 is not approved and remains in clinical development.
KIN-1901 is being developed for inflammation, including rheumatic diseases. Its only recorded clinical trial enrolled healthy volunteers and subjects with ankylosing spondylitis. Because the program is at Phase 1, KIN-1901 is investigational and has no approved use.
KIN-1901 is developed by Roivant Sciences Ltd., which trades on the Nasdaq under the ticker ROIV. Roivant is the sponsor of the Phase 1 study of KIN-1901 in healthy subjects and subjects with ankylosing spondylitis.
KIN-1901 is in Phase 1. One Phase 1 trial has been completed, and no trials are currently active. The study was randomized, double-blind, and placebo-controlled, enrolling 36 participants. KIN-1901 is investigational and has not been approved for any indication.
KIN-1901 has been studied in one clinical trial, NCT04205851, titled a Phase 1 study with KIN-1901 in healthy subjects and subjects with ankylosing spondylitis. That trial is completed, enrolled 36 participants, was placebo-controlled, and was conducted in Canada.
KIN-1901 is not approved. It is an investigational small molecule in Phase 1 development for inflammation, and its single completed trial was a Phase 1 study in healthy subjects and subjects with ankylosing spondylitis. No approval has been granted for any indication.